Drug preparation showing antiviral properties

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmaceutical industry, and concerns an immunomodulatory drug preparation showing antiviral properties. Substance of the invention consists in the fact that the offered drug preparation contains sodium nucleinate 2 to 50 mg/ml, sodium chloride 3 to 10 mg/ml and apyrogenic water with pH making within 6.0 to 7.5.

EFFECT: preparation has a direct antiviral effect, suppresses reproductive ability of viruses.

2 cl, 3 ex, 3 tbl

 

The invention relates to the field of medicine and the pharmaceutical industry and relates to a medicinal product, which has antiviral properties.

Measles and mumps is a common viral disease that can occur in both acute and chronic forms and may cause severe complications: encephalitis and pneumonia (measles); meningitis, orchitis with subsequent infertility (mumps). In addition, it is known that childhood measles and mumps can cause pancreatitis and subsequent development of a number of disease insulin-dependent diabetes mellitus. In some countries, measles, until recently, was one of the main causes of child morbidity and mortality. Only in the world of measles and its complications kills about 1 million people a year.

In recent years there has been a steady increase in the incidence of mumps. The number of patients with mumps in Russia in the period from 1992 to 1998 has grown three times and 98.9 cases per 100 thousand population.

The main method of dealing with them is vaccinated against these diseases in childhood (URI, NView. EFFICACY OF VACCINATION AGAINST MEASLES AND MUMPS. Bulletin vaccination, No. 5 (11) September-October 2000).

In recent years, with the decline of the overall Zabol the needs of measles, due to mass vaccination, an increase of measles among adults. This is because vaccination immunity in them is absent, but natural is not developed, because in childhood they didn't hurt. Mass immunization of the population is also reflected in the frequency and intensity of outbreaks of mumps infection. When reducing the total number of foci increased the number of unit cases.

Modern medicine has a certain Arsenal of remedies against colds, flu, herpes. However, for the treatment of infections such as measles, mumps and such, effective antiviral drugs yet.

Thus, the essential remains a need for new effective means not only for prevention but also treatment of these diseases.

As the closest analogue may be specified patent RU 2154493, revealing use for the treatment of mumps orchitis in children known immunomodulatory agent "Viferon" 2 times daily intrarectal within 5 days.

The present invention is the creation of effective antiviral agents that could be used to treat measles and mumps.

The problem is solved with the new composition in the form of injections based on sodium nucleinate.

Amu is inat sodium - sodium salt of low molecular weight yeast RNA known in medicine for more than 100 years ago and earlier in the past two centuries and in our XXI century this drug is widely used in medicine for various diseases. Including as highly active immunomodulatory agent (http://www.rlsnet.ru/mnn_index_id_999.htm). He has been extensively studied and studied at the present time in different laboratories, which allowed to establish its broad biological potency as an immunomodulating drug, reducing the impairment of cell, phagocytic and humoral immunity, as a moderate inducer of interferon as a means of antiviral therapy for the treatment of viral hepatitis and conjunctivitis, as the Normalizer of disturbed metabolism of cells, activator healing various trophic ulcers, tissue and cell regeneration. As detoxifying remedies that can reduce the toxicity of cytostatica, antibiotics, hormones, and various bacterial exotoxins. As a means, not having allergenic properties and at the same time to a certain extent, reduce the severity of delayed and immediate allergies, drug harmless, non-toxic.

However, in-depth study of nucleinate sodium, performed most recently on new biological models, allow the ILO to detect the drug previously unknown direct antiviral effect (multiple types of viruses) and suppression of drug fertility viruses, i.e. a direct effect on the formation of viral progeny.

Known oral dosage forms of nucleinate sodium powder for oral administration and the film-coated tablet (RLS 2009). However, for the manifestation of newly discovered properties of the drug needed a new parenteral form of administration.

This problem is solved by the proposed tool in the form of a solution for parenteral administration, which includes nukleinat, sodium chloride and pyrogen-free water, while the pH is from 6.0 to 7.5.

The solution contains nukleinat sodium from 2 to 50 mg/ml, sodium chloride from 3 to 10 mg/ml To obtain the usage of nucleinate sodium obtained from bakery yeast in accordance with the patent of the Russian Federation No. 2244008 priority on 05/02/2004, "an Improved method of producing nucleinate sodium".

Proposed according to the invention parenteral form provides a direct antiviral effect and suppression of drug reproductive ability of viruses.

The possibility of carrying out the invention can be illustrated by the following examples.

Example 1.

Sodium nukleinat - 2.0 mg/ml

Sodium chloride 9.0 mg/ml

Water for injections to 1 ml

Example 2.

Sodium nukleinat 50.0 mg/ml

Sodium chloride 5.0 mg/ml

Water for injections to 1 ml

Example 3

And the doctrine of the antiviral properties of the composition.

Experiments on determination of the antiviral action of nucleinate sodium (NN) conducted on the model mumps (VEP)

Table 1.
Cytopathogenic action VEP in cell culture Vero
VEP TCD50/KLLV, mg/ml
10520,5Control VEP
1,05075100100100
0,12550100100100
0,010002550
Control LV0000-

The results by changing the infectious titer of virus progeny on the model VEP are summarized in table 2.

Table 2.
The synthesis of viral progeny in infected VEP cell cultures
Infecting dose of mumps virus (TCD50/eng)The infectious titer of the virus lgT50/0.1 ml at a concentration of NN (g/KL)
0,020,004
1,04,85,5
0,13,04,0
0,013,2-

Title newly acquired viral progeny by 2.0-2.5 lgT50/0.1 ml was lower than the titer of uterine strain. Depending on the concentration NN infectious titer of virus progeny was reduced from 0.7 lgT50/0.1 ml at infecting dose of virus 1,0 lg50/ cell-1.0 lgT50/0.1 ml dose of the virus 0,1 lgT50/ cell. Criterion specific antiviral action NN-index KTI was for the VET to 8.0.

In table 3 the show is but the effect of HH on the formation of progeny virus measles (VK).

Table 3.
The synthesis of viral progeny in infected VK cell cultures
Infecting dose of measles virus (TCD50/eng)The infectious titer of the virus lgT50/0.1 ml at a concentration of NN (µg/ml)
0,020,004
1,05,15,5
0,12,84,5
0,013,0-

The main criterion specific antiviral action NN - KTI index, determined by the ratio srednemesyachnoi matter concentration (CL50to average effective virpiniemi concentration (U50)amounted to VK - 8,0 that can be attributed to nukleinat sodium drugs with high enough virpiniemi activity.

1. Drug for parenteral administration for the treatment of measles or mumps, characterized in that it contains sodium nukleinat, sodium chloride and aeroga the percent water in the following components:

sodium nukleinat2-50 mg/ml
sodium chloride3-10 mg/ml
pyrogen-free waterto 1 ml
at pHfrom 6.0 to 7.5

2. The tool according to claim 1, characterized in that it is a solution for injection.



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to allergology, and can be used for prevention of development of respiratory allergies in a subject. That is ensured by introduction of an effective amount of Lactobacillus rhamnosus GG (LGG) either in a pregnant mother's body, and/or postnatal in a feeding mother's body, or in a subject directly.

EFFECT: introduction of LGG allows preventing an early allergic sensitisation and the following development of respiratory allergies due to higher production of serum antibodies IgA in a subject, and also prevention of allergic inflammation in lungs and respiratory ways.

12 cl, 13 ex, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to optimised fused protein for blocking BLyS or APRIL, which contains extracellular region of N-end of truncated TACI (transmembrane activator and CAML-partner) and Fc sequence IgG. TACI segment of fused protein contains sequence of amino-end region of extracellular region, starting with 13-th amino acid residue, complete sequence of stem area from TACI and is obtained from native sequence of TACI between 12-th and 120-th amino acids. Segment Fc of immunoglobulin IgG of fused protein contains hinge region, CH2 region and CH3 region, TACI segment and Fc segment are fused either directly or through linker sequence. In addition, claimed is DNA sequence which codes fused protein, expression vector, host-cell, pharmaceutical composition, containing fused protein, and application of fused protein for blocking BLyS or APRIL. Obtained fused protein does not degrade in process of expression, possesses high biological activity and high level of expression.

EFFECT: fused protein in accordance with claimed invention can be used in treatment of diseases, associated with abnormal immunologic functions and in treatment of diseases caused by abnormal proliferation of B-lymphocytes.

10 cl, 6 dwg, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to immunomodulatory interleukin-1 drugs. An interleukin composition contains interleukin-1, a cyclooxygenase inhibitor - diclofenac, taken in certain proportions.

EFFECT: compositions exhibit higher efficacy and have no side effects.

6 cl, 5 tbl, 6 ex

Amide derivatives // 2427575

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I), where m equals 1-2, and each R1 (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, hydroxy-(2-6C)alkoxy, amino-(2- 6C)alkoxy, (1-6C)alkylamino-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di[(1-6C)alkyl]amino-(1-6C)alkyl, hydroxy-(2-6C)alkylamino, halogen-(2-6C)alkylamino, amino-(2-6C)alkylamino, (1-6C)alkoxy-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino, di-[(1-6C)alkyl]amino-(2-6C)alkylamino, heterocyclyl, heterocyclyl-(1-6C)alkyl, heterocyclyloxy, heterocyclyl-(1-6C)alkoxy and heterocyclylamino, where heterocyclyl is a 3-7-member monocyclic saturated ring containing one or two heteroatoms selected from nitrogen, oxygen and sulphur, wherein the heterocyclyl can have 1-2 substitutes defined in claim 1, and any of the substitutes R1 given above, which contains a CH3 group bonded to a carbon or nitrogen atom, can contain a substitute given in claim 1, R2 is a halogen, trifluoromethyl or (1-6C)alkyl; R3 is hydrogen, and R4 is hydroxy, (1-6C)alkyl or (1-6C)alkoxy; or pharmaceutically acceptable salts thereof. The invention also relates to methods for synthesis of said compounds, pharmaceutical compositions based on said compounds, and use of said compounds in treating diseases or medical conditions mediated by cytokines.

EFFECT: more effective use of the compounds.

13 cl, 8 tbl, 15 ex

Heterocompound // 2425832

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula

or pharmaceutically acceptable salt thereof, where symbols assume the following values; ring denotes

or , X denotes a single bond, -CH2-, -NR3-, -O-, -S-, R1 denotes a halogen; phenyl; pyridyl; (C3-C8)cycloalkyl; or (C1-C6) alkyl or (C2-C6) alkenyl, each of which can contain a halogen, -CONH2, phenyl or (C3-C8)cycloalkyl as a substitute, R2 denotes CN, -O-(C1-C6)alkyl, -C(=O)H, halogen; or (C1-C6)alkyl, which can be substituted with a halogen or -OH, R3 can form morpholino or 1-pyrrolidinyl together with R1 and nitrogen, and when X denotes a single bond, R1 and R2 can jointly form a 5-member ring and additionally contain -(C1-C6)alkyl as a substitute, R4 denotes the following ring: , , , , , , , , , , or , where any one of the bonds in the ring is linked to an oxazole ring, R5 denotes -H, (C1-C6)alkyl, which can be substituted by not less than one group selected from: -C(=O)NRXRY, -NHRX and -ORX- (C2-C6)alkenyl-; -C(=O)H; -C(=O)NRXRY, RX and RY can be identical or different and denote -H; or (C1-C6)alkyl. The invention also relates to a pharmaceutical composition based on said compounds, having SlP1 agonist activity.

EFFECT: compounds and compositions can be used in medicine for preventing and treating rejection during organ transplant, bone marrow or tissue transplant and autoimmune diseases.

16 cl, 84 tbl, 198 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, also aims at treating babies suffering intestinal colics. A mother and a breast-fed child are treated simultaneously. A cephalosporin antibiotic, an antistaphylococcal immunoglobulin, a staphylococcal bacteriophage, an antifungal agent, a phagocytosis activator are prescribed in the mother for 7-10 days. A staphylococcal bacteriophage, Hylak forte are prescribed to the baby. The second stage involves prescribing a bacterial preparation, an immunomodulator and a therapeutic staphylococcal anatoxin. The baby intakes Hylak forte and the bacterial preparation.

EFFECT: method allows relieving intestinal colics and preventing the development of complications.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to immunology and clinic laboratory diagnostics, and can be used to predict course of acute respiratory viral infections (ARVI) in children in the first days of disease and timely administration of immunomodulating medications. For this purpose by means of ELISA immunologic indices of spontaneous and induced interferon-γ in vitro (IFH-γ) are determined. Index of interferon-γ stimulation (IS IFH-γ) is calculated by division of index of induced level by index of spontaneous level of interferon-γ. Also carried out is calculation of lymphocyte activation index (LAI IFH-γ) per 1000 lymphocytes by division of index of induced interferon-γ by absolute number of patient's lymphocytes. Additionally in blood plasma determined is content of interleukin-10 (IL-10). If values of IS IFH-γ are higher than 3, LAI IFH-γ equals or is higher than 40, IL-10 is from 30 to 60 pg/ml favourable outcome of disease is predicted with therapeutic treatment which does not include immunomodulators. If IS IFH-γ is lower than 3, LAI IFH-γ is lower than 40, IL-10 is from 60 to 100 pg/ml, predicted are severe course of disease and development of complications, which requires urgent treatment by immunomodelling therapy. If IS IFH-γ is lower than 3, LAI IFH-γ is lower than 30, IL-10 is higher than 100 pg/ml, predicted are severe course of disease with development of bronchopulmonary complications and possible chronisation of pathologic process and recurrent ARVD, which requires additional introduction of immunomodelling medications.

EFFECT: increase of accuracy of early prediction of disease course severity and development of complications in children with ARVI, including those from 1 month old, which makes it possible to carry out necessary anti-viral and immunomodelling therapy, aimed at strengthening immunity cell responses, in due time.

3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the application of a biologically active peptide which represents the amino acid sequence SEQ ID No.1.

EFFECT: preparation of a drug for modulation of at least one of the following conditions: fatigue, liver glycogen level and blood lactic acid level.

30 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, and can be applied for correction of malfunctions in immune system in case of pathological conditions, associated with insufficiency of Th 1 - dependent type of immune response. As immunomodulating medication, which stimulates Th 1 - dependent type of immune response, applied are water-soluble polysaccarides with molecular weight 540 and 390 kDa, separated from pharmacopeial raw material of elecampane.

EFFECT: medication extends arsenal of immunomodulating medications of vegetable origin, stimulates production of microphages of interleukin-12 and tumour necrosis factor-alpha.

4 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed group of inventions relates to medicine. Claimed are methods of immune response regulation and reduction of inflammatory symptoms in mammal, with atopic dermatitis. For this purpose introduced is, at least, one medication of frost-resistant plant kiwi and, at least, one corticosteroid. In regulation of immune response in case of atopic dermatitis included is the following treatment period, during which carried out is monotherapy by medication of frost-resistant kiwi without introduction of corticosteroids. Also claimed is composition, which contains, at least, one medication of frost-resistant kiwi and, at least, one corticosteroid. Also claimed is product in form of animal forage, which contains claimed composition. Claimed group of inventions insure efficient regulation of immune response and reduction of inflammatory symptoms in case of atopic dermatitis due to synergetic effect of combination of medications of frost-resistant kiwi and corticosteroids, which makes it possible to reduce need in additional application of corticosteroids in treatment of said pathology and in future carry out monotherapy by medication of frost-resistant kiwi without reduction of treatment efficiency.

EFFECT: invention can be applied for regulation of immune response and reduction of , at least, one symptom of inflammation in mammal which has atopic dermatitis.

35 dwg, 5 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to RSV replication inhibitors of formula (I) or salts thereof or stereochemically isomeric forms, where R is a radical of formula (a) or (b) . Q is hydrogen or C1-6alkyl substituted with a heterocycle selected from oxazolidine, morpholinyl and hexahydrooxazepine. Alk denotes C1-6alkanediyl. X is O; -a1=a2-a3=a4 - is -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH- or -CH=CH-CH=N-; R1 is selected from optionally substituted pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl and pyrrolyl. R2 is C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, Ar-C1-6alkyloxyC1-6alkyl, C3-7cycloalkyl, Ar-C1-6alkyl. R3 is cyano. Ar is phenyl o substituted phenyl. The invention also relates to pharmaceutical compositions containing compounds (I) and a method of producing compounds (I).

EFFECT: high efficiency of the compositions.

9 cl, 20 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine, namely to infection diseases, hepatology, and can be applied for prevention or treatment of viral disease, caused by virus of hepatitis C. For this purpose therapeutic medication, as active ingredients in it are combined 22β-methoxyolean-12-en-3β,24(4β)-diol and interferon, is introduced to patient. High therapeutic effect of claimed medication is associated with synergetic effect of 22β-methoxyolean-12-en-3β,24(4β)-diol and interferon, manifested in inhibition of hepatitis C virus.

EFFECT: insuring high therapeutic effect.

6 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to medication, possessing antioxidant, cardioprotective, antidiabetic, anti-inflammatory, hepatoprotective, antitumoral and antiviral action. Medication, which has antioxidant, cardioprotective, antidiabetic, anti-inflammatory, hepatoprotective, antitumoral and antiviral action, representing luteolin 7,3'-disulphate, is obtained from water-ethanol extract of sea grass of family Zosteraceae.

EFFECT: medication has efficient antioxidant, cardioprotective, antidiabetic, anti-inflammatory, hepatoprotective, antitumoral and antiviral action.

4 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, namely to infectious diseases, and can be used for treating a influenza virus infection, reduction of severity, intensity or length of the complications related to the influenza virus infection, and also to a composition for prevention of the influenza virus infection. That is ensured by diagnosing of the influenza virus infection is followed by introduction of an effective amount of cystamine or its salts to a subject. What is also offered is a composition for prevention of the influenza virus infection including an effective amount of cystamine or its salts, and an antiviral agent.

EFFECT: inventions provide clinical effectiveness, reduces risk of complications related to the influenza virus infection, and also promote prevention of the influenza virus infection.

16 cl, 2 dwg, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: method includes daily introduction of ribavirin, and also introduction of interferon daily or every second day and introduction of interleukin-1 within periodic courses three-four weeks each which include introduction of interleukin-1 every second day with an interval of five to nine weeks.

EFFECT: use of the invention enables higher clinical effectiveness in chronic viral hepatitis C, providing a sparing dose regimen of interleukin-1 and reducing probability of side effects.

1 ex

FIELD: medicine.

SUBSTANCE: invention represents a pharmaceutical composition for treating viral diseases, containing dipeptide, differing by the fact that dipeptide is an aqueous solution of dipeptide of formula (I) Gly-Pro in concentration 0.9-1.1 %; besides, Nipagin is used as a preservative; the ingredients of the composition are taken in certain proportions, g/l.

EFFECT: extended range of the antiviral drugs, more efficient prevention and treatment of viral infection.

3 cl, 5 ex, 5 tbl

FIELD: medicine.

SUBSTANCE: for treating urogenital clamidiosis, cytomegalovirus, herpes simplex, Helicobacter pylori, polyethylene oxide 1500 and polyethylene oxide 400 are melted in the ratio 9:1; the liquid melt is added with a design amount of the preservative sodium chloride; further a design amount of sodium deoxyribonucleate is added in mixing. A melted paste is mould to prepare Derinat suppositories of 1.3-2.5 g.

EFFECT: prepared suppositories provide high bioavailability and prolonged action of the active agent.

3 cl, 7 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: acetylhydrazone 1-cyano-19β,28-epoxy-2,3-seco-18α-olean-3-al of formula I: has high prophylactic activity ID50 0.0001589 mcg/ml and efficiently inhibits reproduction of vesicular stomatitis virus "Indiana" strain in primarily infected cells ID50 0.21 mcg/ml.

EFFECT: high efficiency of the compounds.

3 tbl, 2 cl, 1 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to animal breeding and veterinary science. There are declared an antiviral agent for animals, animal feedstuff, and a method for murrain treatment and prevention in animals. The antiviral agent and feedstuff contain 3-oxo-3,4-dihydro-2-pyrazinecarboxamide or its salt. The method for murrain prevention and treatment includes prescription of 3-oxo-3,4-dihydro-2-pyrazinecarboxamide or its salts.

EFFECT: group of inventions is effective for murrain prevention and treatment in pig and sheep family animals.

10 cl, 5 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is novel combination of active substances for creation of pharmaceutical composition, liquid water ambroxol-based medications for treatment of diseases of respiratory ways with formation of viscous sputum, which possess expectorant, mucolytic, anti-inflammatory effect. Preparation contains ambroxol, pharmaceutically suitable water-soluble salt of glycyrrizic acid and extract of thyme.

EFFECT: preparation in accordance with invention makes it possible to obtain efficient clinical results (reduction of coughing period duration and quicker recovery of patients with diseases of respiratory ways) and provides multi-directional action on cough pathogenesis in whole.

16 cl, 3 tbl, 10 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine, namely to infection diseases, hepatology, and can be applied for prevention or treatment of viral disease, caused by virus of hepatitis C. For this purpose therapeutic medication, as active ingredients in it are combined 22β-methoxyolean-12-en-3β,24(4β)-diol and interferon, is introduced to patient. High therapeutic effect of claimed medication is associated with synergetic effect of 22β-methoxyolean-12-en-3β,24(4β)-diol and interferon, manifested in inhibition of hepatitis C virus.

EFFECT: insuring high therapeutic effect.

6 cl, 1 ex

Up!